Overview

• Advances in early detection and treatment have driven the increase from 18 million survivors in 2022 to 18.6 million as of January 2025.
• About 51% of survivors received their diagnosis within the past 10 years and 79% are aged 60 or older.
• The most prevalent cancers among survivors are prostate, skin melanoma and colorectal in men and breast, uterine corpus and thyroid in women.
• Black patients with early-stage lung and rectal cancers are significantly less likely to receive surgery than White patients and uninsured individuals face lower survival rates.
• Survivors often contend with long-term treatment side effects, financial hardship and fear of recurrence, highlighting gaps in post-treatment support.